Potassium News and Research RSS Feed - Potassium News and Research

DaVita Kidney Care offers recipes to help CKD patients maintain healthy diet during Fourth of July weekend

DaVita Kidney Care offers recipes to help CKD patients maintain healthy diet during Fourth of July weekend

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, offers recipes that can help people with chronic kidney disease (CKD) maintain a healthy diet during the Fourth of July weekend. [More]
Eating at full-service restaurants not necessarily healthier than eating at fast-food outlets

Eating at full-service restaurants not necessarily healthier than eating at fast-food outlets

When Americans go out to eat, either at a fast-food outlet or a full-service restaurant, they consume, on average, about 200 more calories a day than when they stay home for meals, a new study reports. They also take in more fat, saturated fat, cholesterol and sodium than those who prepare and eat their meals at home. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
New study examines appropriate use of dietary supplementation in children with ASD

New study examines appropriate use of dietary supplementation in children with ASD

Children with Autism Spectrum Disorder (ASD) are often picky eaters, which can lead parents to suspect that their children might not be getting adequate amounts of vitamins and minerals. This sometimes leads parents of children with ASD to try nutritional supplements and dietary regimens such as gluten-free and casein-free (GFCF) diets without professional supervision. [More]
Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx. [More]

Fertilization with high nitrogen:potassium ratio fertilizers reduces environmental effect of landscape palms

Palms are an important part of the environment in subtropical and warm temperate climates. Palms' aesthetics and small "footprints" make them desirable in a variety of landscapes throughout the southeastern United States. [More]
FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. [More]
Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

The ratio of aldosterone to renin in plasma is a reliable indicator of primary hypoaldosteronism in newborns and infants, say researchers. [More]
Too much or too little sleep may up stroke risk in hypertensive patients

Too much or too little sleep may up stroke risk in hypertensive patients

High blood pressure, or hypertension, affects one third of--or 70 million--US adults, and the healthcare costs associated with treating the disease are approximately $46 billion. [More]
Brain protein plays key role in controlling binge drinking

Brain protein plays key role in controlling binge drinking

Scientists at The Scripps Research Institute have discovered that a brain protein has a key role in controlling binge drinking in animal models. They found that deleting the gene for this protein in mice ramped up alcohol consumption and prevented the brain from signaling the rewarding properties of alcohol. [More]
Findings could help design tailor-made drugs to treat blood pressure

Findings could help design tailor-made drugs to treat blood pressure

One in three Americans has high blood pressure, a long-term constriction of arteries that can lead to coronary heart disease, heart failure and stroke. [More]
New UM SOM study reveals why thiazide drugs not effective in some patients

New UM SOM study reveals why thiazide drugs not effective in some patients

Every year, more than 120 million prescriptions are written worldwide for thiazide drugs, a group of salt-lowering medicines used to treat high blood pressure. These drugs are often work very well, and over decades have saved hundreds of thousands of lives. [More]
Impact Beverage launches breakthrough athletic supplement in Southern California

Impact Beverage launches breakthrough athletic supplement in Southern California

Impact Beverage LLC today announced the introduction of its breakthrough athletic supplement HeadOn to Southern California. The ready-to-drink formula, which launched in Colorado earlier this year, changes the way athletes and active individuals approach strenuous activity. [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
New oral drug shows promise in patients with chronic kidney disease

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia). [More]
Skipping lunch is a common practice among children, adolescents, shows study

Skipping lunch is a common practice among children, adolescents, shows study

According to new analysis of data from the 2009-2012 National Health and Nutrition Examination Survey (NHANES) that evaluated eating patterns of 3,647 children ages 4-13 years, skipping lunch is a common practice among children and adolescents, with 13% of younger children and 17% of 9-13 year olds skipping lunch on a given day. [More]

Soils play a major role in radiation control, shows research

Radiation suddenly contaminates the land your family has farmed and lived on for generations. Can soil play a role in protecting crops and human health? [More]
Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. [More]
New in vitro study examines benefits of pear-enriched diet on chronic diseases

New in vitro study examines benefits of pear-enriched diet on chronic diseases

A new in vitro (test tube) study, "Dietary functional benefits of Bartlett and Starkrimson pears for potential management of hyperglycemia, hypertension and ulcer bacteria Helicobacter pylori while supporting beneficial probiotic bacterial response," was published in the March issue of Food Research International. [More]
Researchers discover new cause to explain development of temporal lobe epilepsy

Researchers discover new cause to explain development of temporal lobe epilepsy

Epilepsy is a very prevalent neurological disorder. Approximately one-third of patients are resistant to currently available therapies. A team of researchers under the guidance of the Institute of Cellular Neurosciences at the University of Bonn has discovered a new cause to explain the development of temporal lobe epilepsy: At an early stage, astrocytes are uncoupled from each other. [More]
Advertisement
Advertisement